» Articles » PMID: 8755825

Inhibition of Anti-Gal IgG Binding to Porcine Endothelial Cells by Synthetic Oligosaccharides

Overview
Journal Transplantation
Specialty General Surgery
Date 1996 Jul 27
PMID 8755825
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Rejection of pig-to-human or pig-to-primate xenografts is mediated by the natural anti-Gal antibody, which interacts with alpha-galactosyl epitopes (i.e., Gal alpha1-3Gal beta1-4GlcNAc-R) abundantly expressed on porcine cells. The objective of this study was to determine the ability of various synthetic oligosaccharides to inhibit the binding of anti-Gal IgG molecules to porcine endothelial cells in vitro. Such inhibition ultimately may help to reduce or to prevent the in vivo antibody-dependent cell cytotoxicity (ADCC) reaction. In the absence of complement-mediated hyperacute rejection, the ADCC induced by anti-Gal IgG molecules is likely to cause the chronic rejection of xenografts. The synthetic free alpha-galactosyl epitope (Gal alpha1-3Gal beta1-4GlcNAc) was found to be 300-fold more effective than melibiose or alpha-methyl galactoside in inhibiting anti-Gal binding to porcine endothelial cells, and to prevent >90% of the antibody binding at a concentration of 1 mM. The disaccharide Gal alpha1-3Gal was ten-fold less effective than the free alpha-galactosyl epitope. Accordingly, the affinity of the disaccharide to anti-Gal, as measured by equilibrium dialysis, was seven-fold lower than that of the trisaccharide. The effective concentration of oligosaccharides inhibiting anti-Gal is independent of the antibody affinity, but is dependent on the concentration of the antibody. Based on the small difference in affinity between Gal alpha1-3Gal beta1-4GlcNAc and Gal alpha1-3Gal beta1-4GIc, and the large difference in the price of N-acetyllactosamine vs. lactose, it is suggested that lactose may be considered as an appropriate starting material for synthesizing large amounts of a trisaccharide that effectively neutralizes anti-Gal.

Citing Articles

Big is not better: Comparing two alpha-Gal-bearing glycotopes in neoglycoproteins as biomarkers for Leishmania (Viannia) braziliensis infection.

Montoya A, Gil E, Vinales I, Estevao I, Taboada P, Torrico M Carbohydr Res. 2024; 536:109015.

PMID: 38198982 PMC: 11366264. DOI: 10.1016/j.carres.2023.109015.


Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy.

Hinterholzer A, Moises J, Regl C, Schwap S, Rapp E, Huber C MAbs. 2022; 14(1):2132977.

PMID: 36239533 PMC: 9578466. DOI: 10.1080/19420862.2022.2132977.


Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.

Olivera-Ardid S, Bello-Gil D, Tuzikov A, Araujo R, Ferrero-Alves Y, Garcia Figueroa B Front Immunol. 2022; 13:873019.

PMID: 35432370 PMC: 9009260. DOI: 10.3389/fimmu.2022.873019.


Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies.

Galili U Front Mol Biosci. 2021; 8:746883.

PMID: 34805272 PMC: 8601398. DOI: 10.3389/fmolb.2021.746883.


Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Galili U Vaccine. 2020; 38(42):6487-6499.

PMID: 32907757 PMC: 7437500. DOI: 10.1016/j.vaccine.2020.08.032.